This study and the resulting initiative, Strengthening Pharmaceutical
Innovation in Africa, come at an important moment in the development of
pharmaceutical innovation strategies in Africa and in achieving access to essential medicines for all in
Africa.
Two landmark agreements for research and medicines production in Africa have
been reached. The Global Strategy on Public Health, Innovation and Intellectual
Property is a mechanism signed by 192 countries that calls for increased
investments for research and production of medicines that are needed by
countries, to be coordinated by them. The Pharmaceutical Manufacturing Plan for
Africa, adopted by the Summit of the African Union in 2007 is the basis for a
more coordinated approach to local medicines production– based on countries’
needs.
These agreements and other developments set the foundation and a long-term
political agreement for the planning and financing of medicines research and
production on the African continent. At the same time, much work remains to be done to make national and regional pharmaceutical and health innovation a reality for our countries. Countries need
to better understand their current situation, their potential for engaging in
local research and medicines production and they need to develop strategies to
do this.
This report and tool mark the starting point of an initiative innovation in
Africa. It started with a study and practical reflection between countries on
what is needed to provide better access and encourage local production of
medicines in Africa. It was reviewed and revised by the Extended Technical
Committee on the Pharmaceutical Manufacturing Plan for Africa incorporating the
core committee of member state representatives and other experts in health and health policy,
science and technology, trade and industry and pharmaceuticals – in Pretoria in
February 2010. The initiative, its study and pharmaceutical innovation tool,
have been endorsed by the African Ministerial Conference on Science and
Technology (AMCOST) at its meeting in Cairo in March 2010.
The regional dimension will have an important place in this process. As an
African vision and agenda for pharmaceutical innovation emerge, the Regional
Economic Communities will have an important role to play, both as catalysts and "multipliers" to
build consensus, and move the plan forward by coordinating member countries...